-65%

est. 2Y upside i

HealthcareSeries A

Digital platforms that enable an outstanding patient experience

Rank

#926

Sector

Healthtech, Medical Imaging AI, Digital Health

Est. Liquidity

~4Y

Data Quality

Data: Low

Eden presents a moderate upside opportunity for a job seeker, driven by its strong market penetration in Mexico and significant growth potential in the Latin American health tech sector.

Last updated: March 10, 2026

Bull (30%)+250%

Eden successfully expands its AI-powered PACS and DICOM solutions across Latin America, leveraging its strong Mexico foothold and recent Brazil expansion. New AI features like the 'AI Report' significantly boost radiologist efficiency and diagnostic accuracy, leading to rapid customer acquisition and market share gains from legacy incumbents. Revenue grows to over $150M by 2028, justifying a $875M+ valuation at a premium multiple, driven by its innovative technology and dominant regional position.

Base (45%)+75%

Eden continues its steady growth in the Latin American market, maintaining its competitive edge with cloud-based AI solutions but facing persistent competition from large incumbents like Siemens and Philips. The company expands into key markets like Brazil and Colombia, growing its patient base and processing volume. Revenue reaches approximately $80M by 2028, leading to an acquisition or IPO at around a $437.5M valuation.

Bear (25%)-75%

Intense competition from well-funded incumbents and new, advanced open-source AI models (like Pillar-0) erode Eden's pricing power and market share. Regulatory hurdles in new LATAM markets prove more challenging than anticipated, slowing expansion. Growth stalls, leading to a down round or acquisition at a significantly reduced valuation of $62.5M, severely impacting common stock value given the $48.7M in liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold $48.7M in liquidation preferences ahead of common stock, based on an estimated current valuation of $250M.

Dilution Risk

high

As a Series A company, Eden will likely require multiple additional funding rounds, leading to further dilution for common stock holders.

Secondary Liquidity

none

At its current stage, there is no active secondary market or tender offers for Eden's equity.

Questions to Ask at the Interview

Strategic questions based on Eden's data — designed to show you've done your homework.

  • 1

    “Given the rapid advancements in open-source AI models for medical imaging, how does Eden plan to maintain its competitive moat against both incumbents and new, potentially free, AI solutions?”

  • 2

    “With significant expansion planned for Brazil and Colombia, what specific strategies are in place to navigate the diverse regulatory landscapes and healthcare infrastructure challenges in these new markets?”

  • 3

    “Considering the Series A funding and the need for future capital, how does Eden envision its path to liquidity for employees, and what are the company's targets for revenue and valuation over the next 2-4 years?”

Community

Valuation Sentiment

Our model estimates -65% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.